ArticleBasic research in cardiology2021
Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.
Open access · hybridAbstract read
In one paragraph
Article in Basic research in cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Substrate-Dependent Pro- and Antiarrhythmic Action of Omecamtiv Mecarbil at the Ventricular and Atrial Level: Insights from a Langendorff-Perfused Rabbit Heart Model.Cardiovascular toxicology · 2026Article
- Insights from electromechanical simulations to assess omecamtiv mecarbil efficacy in heart failure.The Journal of physiology · 2026Article
- Targeting cardiac myosin in HFrEF: mechanism, clinical evidence, and the role of omecamtiv mecarbil.Journal of cardiothoracic surgery · 2026Review
- Danicamtiv increases cardiac mechanical efficiency.The Journal of physiology · 2025Article
- Comparative mechanistic analysis of danicamtiv and omecamtiv mecarbil's in vivo cardiac effects.The Journal of general physiology · 2025Article
- Differential effects of myosin activators on myocardial contractile function in nonfailing and failing human hearts.American journal of physiology. Heart and circulatory physiology · 2025Article
- Pharmacodynamics of single-dose omecamtiv mecarbil administered intravenously in clinically healthy cats.Open veterinary journal · 2024Article
- Myosin Isoform-Dependent Effect of Omecamtiv Mecarbil on the Regulation of Force Generation in Human Cardiac Muscle.International journal of molecular sciences · 2024Article
- The carbon monoxide prodrug oCOm-21 increases CaPhysiological reports · 2024Article
- Assessing Cardiac Contractility From Single Molecules to Whole Hearts.JACC. Basic to translational science · 2024Review
- Omecamtiv Mecarbil in the treatment of heart failure: the past, the present, and the future.Frontiers in cardiovascular medicine · 2024Review
- Effect of the Novel Myotrope Danicamtiv on Cross-Bridge Behavior in Human Myocardium.Journal of the American Heart Association · 2023Article
- Omecamtiv mecarbil in precision-cut living heart failure slices: A story of a double-edged sword.Journal of molecular and cellular cardiology plus · 2023Article
- Altered Left Ventricular Rat Gene Expression Induced by the Myosin Activator Omecamtiv Mecarbil.Genes · 2023Article
- The Novel Cardiac Myosin Activator Danicamtiv Improves Cardiac Systolic Function at the Expense of Diastolic Dysfunction In Vitro and In Vivo: Implications for Clinical Applications.International journal of molecular sciences · 2022Article
- Antiarrhythmic and Inotropic Effects of Selective NaInternational journal of molecular sciences · 2022Review
- Distinct Mechanisms for Increased Cardiac Contraction Through Selective Alteration of Either Myosin or Troponin Activity.JACC. Basic to translational science · 2022Article
- A NovelFrontiers in physiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 2 institutions in 1 country.
Gábor Á Fülöp *Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Attila Oláh *Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Tamas Csipo *Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Árpád KovácsDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Róbert PórszászDepartment of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Roland VeressDepartment of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Balázs HorváthDepartment of Physiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
László NagyDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Beáta BódiDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Miklós FagyasDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Solveig Lind HelgadottirDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Viktor BánhegyiDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Béla JuhászDepartment of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Mariann BombiczDepartment of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Daniel PrikszDepartment of Pharmacology and Pharmacotherapy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Peter NanasiDepartment of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Béla MerkelyHeart and Vascular Center, Semmelweis University, Budapest, Hungary.
István ÉdesDivision of Cardiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Zoltán CsanádiDivision of Cardiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Zoltán PappDivision of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary.
Tamás Radovits *Heart and Vascular Center, Semmelweis University, Budapest, Hungary.
Attila Tóth *Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen, 22 Móricz Zsigmond Street, 4032, Debrecen, Hungary. atitoth@med.unideb.hu.ORCID http://orcid.org/0000-0001-6503-3653
University of Debrecen · HUSemmelweis University · HU
Funding
Higher Education Institutional Excellence Programme of the Ministry for Innovation and Technology in Hungary Therapeutic Development thematic programme of the Semmelweis UniversityMinistry for National Economy of Hungary, co-financed by the European Union and the European Regional Development Fund GINOP-2.3.2-15-2016-00043Ministry of Human Capacities of Hungary, co-financed by the European Union and the European Regional Development Fund ÚNKP-18-3-III-DE-209National Research, Development and Innovation Fund of Hungary FK 128116National Research, Development and Innovation Fund of Hungary FK 128809National Research, Development and Innovation Fund of Hungary. K 116940 and K 132623National Research, Development and Innovation Fund of Hungary. K 134939The Thematic Excellence Programme of the Ministry for Innovation and Technology, also supported from the National Research, Development and Innovation Fund of Hungary ED_18-1-2019-0028, TKP2020-IKA-04 and TKP2020-NKA-04The Thematic Excellence Programme of the Ministry for Innovation and Technology was also supported from the National Research, Development and Innovation Fund of Hungary 2020-4.1.1.-TKP2020, Therapeutic Development and Bioimaging thematic programme of the Semmelweis University
Abstract
Omecamtiv mecarbil (OM) is a promising novel drug for improving cardiac contractility. We tested the therapeutic range of OM and identified previously unrecognized side effects. The Ca
Indexed as
Action PotentialsAdultAnimalsArrhythmias, CardiacBlood PressureCalcium SignalingCardiotonic AgentsDiastoleDogsDose-Response Relationship, DrugFemaleHeart RateHumansHypotensionKineticsMaleCardiotonic Agentsomecamtiv mecarbilUreaCa2+ sensitivityDiastolic dysfunctionHeart failureInotropyOmecamtiv mecarbilPulsus alternans
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.